Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study

BackgroundThe efficacy of combination chemotherapy beyond the first-line setting remains modest in patients with advanced pancreatic adenocarcinoma (PAC). Evidence from recent clinical studies has shown that liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) resulted in su...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Amol Gupta, Ana De Jesus-Acosta, Lei Zheng, Valerie Lee, Ihab Kamel, Dung Le, Michael Pishvaian, Daniel Laheru
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Subjects:	pancreatic adenocarcinoma liposomal irinotecan irinotecan 5-fluorouracil (5-FU) and leucovorin (LV) progression
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1250136/full